Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039160 | 0.71 | MAOA (0.46) | SLC6A2HTR2ASLC6A4SLC6A3HPGD | |
| SCHEMBL6725869 | 0.71 | HPGD (0.34) | SLC6A2HTR2ASLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL6727353 | 0.68 | MAOB (0.48) | HPGDALDH1A1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL16932344 | 0.61 | IDO1 (0.64) | — | |
| SCHEMBL6040335 | 0.58 | MMP2 (0.33) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4414360 | 0.58 | HPGD (0.64) | HPGDPOLBKMT2AMEN1HSD17B10 | |
| SCHEMBL4413144 | 0.58 | HPGD (0.64) | HPGDPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL16939101 | 0.57 | KMO (0.52) | POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL3034800 | 0.57 | MAOA (0.51) | — | |
| SCHEMBL25337078 | 0.56 | APEX1 (0.56) | APEX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SLC6A2 4692/4885HTR2A 1811/4885SLC6A4 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.